Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics |
| |
Authors: | K. Van Acker D. Bouhassira D. De Bacquer S. Weiss K. Matthys H. Raemen C. Mathieu I.M. Colin |
| |
Affiliation: | 1. Department of Endocrinology, St-Jozef Clinic, Bornem, Belgium;2. Inserm U-792, hôpital Ambroise-Paré, Boulogne-Billancourt, France;3. Université Versailles-Saint-Quentin, Versailles, France;4. Department of Public Health, University Hospital, Ghent, Belgium;5. Pfizer, Belgium;6. Department of Endocrinology, University Hospital Gasthuisberg (KUL), Leuven, Belgium;7. Unité d’endocrino-diabétologie, département de médecine interne, hôpital de Warquignies-Mons, CHR Saint-Joseph, 5, avenue Baudouin-de-Constantinople, 7000 Mons, Belgium;8. Laboratory of Experimental Morphology, University Catholic of Louvain (UCL), Brussels, Belgium |
| |
Abstract: | AimsDiabetic polyneuropathy (DPN) without or with neuropathic pain (DPN-P) is one of the most frequent complications of diabetes. To better delineate their respective prevalences, we conducted a cross-sectional study that included 1111 patients (767 type 2 and 344 type 1 diabetic patients) followed up in diabetic outpatients clinics. The association of DPN and DPN-P with other diabetic complications, the impact on quality of life (QoL) and pain management were also investigated.MethodsTwo validated tools (Neuropen® and the DN4 questionnaire) were used to diagnose the two conditions. Pain intensity was measured using a visual analogue scale, and participants completed the 12-item Short-Form Health Survey to evaluate the physical and mental components of QoL. Univariate and multivariate models were used for the statistical analyses.ResultsThe prevalence of DPN was 43% (95% CI 40.1–45.9), and was higher in type 2 (50.8%) than in type 1 (25.6%) diabetic patients. The prevalence of DPN-P was 14% (95% CI 12.1–16.2) which, again, was higher in type 2 (17.9%) than in type 1 (5.8%) patients. These prevalences both increased with age and diabetes duration. Nephropathy, obesity, low HDL cholesterol and high triglyceride levels were independently associated with DPN and/or DPN-P. Physical and mental components of QoL were significantly altered by DPN-P, but not DPN. Only half of the DPN-P patients were using analgesic treatment, while 28% were using anticonvulsants or antidepressants.ConclusionDPN and DPN-P are frequent complications of diabetes, especially in type 2, and can be identified with inexpensive and easy-to-use screening tools. Despite its profound impact on QoL, DPN-P remains undertreated. |
| |
Keywords: | Diabetic peripheral neuropathy Diabetic peripheral neuropathic pain Quality of life DN4 Neuropen® Mots clé s: Neuropathie pé riphé rique diabé tique Douleur neuropathique diabé tique Qualité de vie DN4 Neuropen® |
本文献已被 ScienceDirect 等数据库收录! |
|